Artelo Biosciences, Inc.

ARTL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 94.7% and free cash flow fell 879.2%, each against the same quarter a year earlier.

2.70 0.04 −1.46%
Market cap
$1.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
3.00 1.79 0.17 0.38

+8 more quarters

Net Debt/EBITDA
1.69 3.95 0.22 0.57
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
2.07 0.40 0.70 1.12
Capex/Depreciation
0.00 0.00 2.65 (3.01)
Interest Coverage
(417.50) (21.69) (29.64) (27.83)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.32 0.16 0.73 0.55
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(16.70) (14.51) (71.47) (128.80)
Cash per Share
13.93 125.13 15.75 59.11
Shareholders Equity per Share
16.58 81.27 (33.39) (21.75)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
16.58 81.27 (33.39) (21.75)
Free Cash Flow
(5.03) (1.19) (2.72) (3.75)
Working Capital
2.92 4.59 (3.35) (3.03)
Capital Expenditures
— — 0.19 (0.25)
Net Current Asset Value
2.91 4.58 (3.38) (3.07)
Other line items
Quick Ratio
2.89 1.76 0.15 0.35
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(16.70) (14.51) (76.40) (120.21)
Capex per Share
0.00 0.00 4.93 (8.59)
Average Payables
3.07 3.28 2.36 2.25
Average Assets
5.41 8.02 3.75 5.70
Average Common Equity
1.80 3.66 0.79 2.86
Capex to Sales
— — 0.00 0.00

Fold the line items

Columns are period end dates · fundamentals updated 28 Sep 2026